Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2003
    • View Item
    •   MOspace Home
    • University of Missouri-Columbia
    • School of Medicine (MU)
    • Department of Family and Community Medicine (MU)
    • Family Physicians Inquiries Network (MU)
    • Clinical Inquiries (MU)
    • Clinical Inquiries, 2003
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    What is the best initial treatment of Parkinson's disease?

    Schreck, Jennifer
    Kelsberg, Gary
    Rich, Joanne
    View/Open
    [PDF] WhatBestInitialTreatmentParkinson.pdf (81.09Kb)
    Date
    2003
    Format
    Article
    Metadata
    [+] Show full item record
    Abstract
    No studies clearly demonstrate the best initial treatment for Parkinson's disease. Levodopa improves motor function in Parkinson's disease; however, long-term use is associated with irreversible dyskinesias and motor fluctuations. Compared with placebo, selegiline improves the motor symptoms of Parkinson's disease and allows a physician to delay the introduction of levodopa by 9 to 12 months (strength of recommendation [SOR]: A, based on randomized controlled trials). Dopamine agonists--alone or combined with levodopa--have fewer associated dyskinesias and other motor complications but produce lower scores on activities of daily living and Unified Parkinson's Disease Rating Scale (UPDRS) when compared with levodopa alone (SOR: A, based on systematic reviews of randomized controlled trials). Drug choices should be based on each patient's individual symptoms and response to medication.
    URI
    http://hdl.handle.net/10355/2962
    Part of
    Journal of family practice, 52, no. 11 (November 2003): 897-899.
    Rights
    OpenAccess.
    This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.
    Collections
    • Clinical Inquiries, 2003

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems